BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 18607850)

  • 1. Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
    Jensen SA; Vainer B; Witton CJ; Jørgensen JT; Sørensen JB
    Acta Oncol; 2008; 47(6):1054-61. PubMed ID: 18607850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
    Jakob C; Aust DE; Meyer W; Baretton GB; Schwabe W; Häusler P; Becker H; Liersch T
    J Pathol; 2004 Dec; 204(5):562-8. PubMed ID: 15538739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine.
    Tokunaga Y; Takahashi K; Saito T
    Hepatogastroenterology; 2005; 52(66):1715-21. PubMed ID: 16334763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
    Jakob C; Liersch T; Meyer W; Baretton GB; Schwabe W; Häusler P; Kulle B; Becker H; Aust DE
    Am J Surg Pathol; 2006 Sep; 30(9):1169-74. PubMed ID: 16931962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H; Iinuma H; Watanabe T
    Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
    Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
    Okumura K; Shiomi H; Mekata E; Kaizuka M; Endo Y; Kurumi Y; Tani T
    Oncol Rep; 2006 Apr; 15(4):875-82. PubMed ID: 16525674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
    Salonga D; Danenberg KD; Johnson M; Metzger R; Groshen S; Tsao-Wei DD; Lenz HJ; Leichman CG; Leichman L; Diasio RB; Danenberg PV
    Clin Cancer Res; 2000 Apr; 6(4):1322-7. PubMed ID: 10778957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy.
    Kinoshita M; Kodera Y; Hibi K; Nakayama G; Inoue T; Ohashi N; Ito Y; Koike M; Fujiwara M; Nakao A
    Anticancer Res; 2007; 27(2):851-6. PubMed ID: 17465211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.
    Koumarianou A; Tzeveleki I; Mekras D; Eleftheraki AG; Bobos M; Wirtz R; Fountzilas E; Valavanis C; Xanthakis I; Kalogeras KT; Basdanis G; Pentheroudakis G; Kotoula V; Fountzilas G
    Anticancer Res; 2014 Sep; 34(9):4949-62. PubMed ID: 25202077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive value of the thymidylate synthase expression in patients with non-metastatic colorectal cancer.
    Aguiar S; Lopes A; Soares FA; Rossi BM; Ferreira FO; Nakagawa WT; Carvalho AL; Filho WJ
    Eur J Surg Oncol; 2005 Oct; 31(8):863-8. PubMed ID: 15923105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer.
    van Triest B; Pinedo HM; Blaauwgeers JL; van Diest PJ; Schoenmakers PS; Voorn DA; Smid K; Hoekman K; Hoitsma HF; Peters GJ
    Clin Cancer Res; 2000 Mar; 6(3):1063-72. PubMed ID: 10741735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer.
    Xi Y; Formentini A; Nakajima G; Kornmann M; Ju J
    Oncol Rep; 2008 Jan; 19(1):257-62. PubMed ID: 18097604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer.
    Goto T; Shinmura K; Yokomizo K; Sakuraba K; Kitamura Y; Shirahata A; Saito M; Kigawa G; Nemoto H; Sanada Y; Hibi K
    Anticancer Res; 2012 May; 32(5):1757-62. PubMed ID: 22593457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.
    Okumura K; Mekata E; Shiomi H; Naitoh H; Abe H; Endo Y; Kurumi Y; Tani T
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):587-94. PubMed ID: 17520254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymidine phosphorylase mRNA level predicts survival of patients with advanced oropharyngeal cancer.
    Ijuin T; Nibu K; Doi K; Inoue H; Saitoh M; Ohtsuki N; Makino K; Amatsu M
    Acta Otolaryngol; 2007 Mar; 127(3):305-11. PubMed ID: 17364369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
    Dotor E; Cuatrecases M; Martínez-Iniesta M; Navarro M; Vilardell F; Guinó E; Pareja L; Figueras A; Molleví DG; Serrano T; de Oca J; Peinado MA; Moreno V; Germà JR; Capellá G; Villanueva A
    J Clin Oncol; 2006 Apr; 24(10):1603-11. PubMed ID: 16575011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma.
    Yasuno M; Mori T; Koike M; Takahashi K; Toi M; Takizawa T; Shimizu S; Yamaguchi T; Matsumoto H
    Oncol Rep; 2005 Mar; 13(3):405-12. PubMed ID: 15706408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.